<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825574</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-285-1408</org_study_id>
    <nct_id>NCT04825574</nct_id>
  </id_info>
  <brief_title>Study for Patients Previously Treated in Avapritinib Clinical Trials</brief_title>
  <official_title>Extension Protocol for Patients Previously Treated in Avapritinib Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label extension study to provide long term safety data for GIST patients who&#xD;
      are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical&#xD;
      trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by the number of serious adverse events and adverse events of special interest</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>Patients with GIST previously enrolled in avapritinib clinical trials</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avapritinib</intervention_name>
    <description>avapritinib tablet</description>
    <arm_group_label>Patients with GIST previously enrolled in avapritinib clinical trials</arm_group_label>
    <other_name>BLU-285</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has histologically confirmed metastatic or unresectable GIST as established by&#xD;
             entry in a previous avapritinib clinical trial and has been receiving treatment with&#xD;
             avapritinib on one of these trials.&#xD;
&#xD;
          2. Patient continues to receive clinical benefit from avapritinib treatment, as assessed&#xD;
             by the investigator.&#xD;
&#xD;
          3. Patient or legal guardian, if permitted by local regulatory authorities, provides&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient requires therapy with a concomitant medication that is a strong inhibitor or&#xD;
             strong inducer of cytochrome P450 (CYP) 3A4&#xD;
&#xD;
          2. Patient has a history of intracranial bleeding either prior to or during avapritinib&#xD;
             treatment&#xD;
&#xD;
          3. Patients who have poor organ function, defined as Adverse Events of NCI CTCAE version&#xD;
             5.0 Grade 3 or higher at the time of enrollment must delay start of treatment until&#xD;
             symptoms return to Grade 2 or baseline, or the start of treatment has been approved by&#xD;
             the Sponsor.&#xD;
&#xD;
          4. Patients who have ongoing cognitive or mood effects Adverse Events of NCI CTCAE&#xD;
             version 5.0 higher than Grade 1 must delay start of treatment until symptoms return to&#xD;
             Grade 1 or baseline.&#xD;
&#xD;
          5. Women who are unwilling, if not postmenopausal or surgically sterile, to abstain from&#xD;
             sexual intercourse or employ highly effective contraception from the time of&#xD;
             enrollment and for at least 30 days after the last dose of avapritinib. Men who are&#xD;
             unwilling, if not surgically sterile, to abstain from sexual intercourse or employ&#xD;
             highly effective contraception from the time of first dose and for at least 90 days&#xD;
             after the last dose of avapritinib.&#xD;
&#xD;
          6. Women who are pregnant.&#xD;
&#xD;
          7. Women who are breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris Institut de Cancerologie Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

